Patent approved in Japan for Isofol’s drug candidate arfolitixorin
GOTHENBURG, Sweden, December 20, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL). A patent covering the Active […]
English
Patent detecting how patients respond to folate-based cancer treatment approved in the USA
GOTHENBURG, Sweden, December 13, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), today announces the approval from
Isofol to Expand Global Phase 3 AGENT Trial in First-Line Metastatic Colorectal Cancer to Australia
GOTHENBURG, Sweden, November 18, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), today announced the successful completion
Isofol’s board appoints Dr. Jarl Ulf Jungnelius as new CEO of the company
GOTHENBURG, Sweden, November 13, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), today announced that the board
Isofol Receives Positive Feedback from PMDA in Japan, Expanding Ongoing Global Pivotal Phase 3 AGENT Trial in First Line Metastatic Colorectal Cancer
GOTHENBURG, Sweden, October 18, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), today announced the successful completion
Isofol Announces Presentation on the Global Phase 3 Study of arfolitixorin in Metastatic Colorectal Cancer at 2019 ESMO Congress
GOTHENBURG, Sweden, September 29, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), today announced a poster presentation
Isofol Announces that an Abstract has been Accepted for Presentation at the 2019 ESMO Congress
GOTHENBURG, Sweden, September 12, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), today announced that an abstract
Isofol Announces Management Team Evolution with Appointment of Dr. Roger Tell as Chief Medical Officer
GOTHENBURG, Sweden, August 15, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), today announced the appointment of
Isofol Announces Recent Advisory Board Meeting Covering Development Plan for arfolitixorin
GOTHENBURG, Sweden, July 15, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), today announced the outcome of
Isofol Receives Clinical Use Patent Approval in the United States for Drug Candidate arfolitixorin
GOTHENBURG, Sweden, June 25, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), today announced approval of a